Regeneron Pharmaceutical (REGN) 393.40 $REGN Biotech

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 9:09 PM

Regeneron Pharmaceutical (REGN) 393.40 $REGN

Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), MYL: 41.92 (-0.44), AMGN: 170.13 (+0.07), ARIA: 10.19 (-0.15), RIGL: 3.45 (+0.08), REGN: 393.40 (+0.85)

Regeneron Announces Upcoming 2016 Investor Conference Presentations
PR Newswire - Thu Sep 01, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conferences:
REGN: 393.40 (+0.85)

The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 38.97 (-0.20), AMGN: 170.13 (+0.07), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 61.42 (+1.68), AMGN: 170.13 (+0.07), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.52 (+0.04), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), PTLA: 20.86 (+0.50), CLVS: 23.59 (-1.18), GILD: 77.42 (-0.96), ALXN: 125.63 (-0.23), REGN: 393.40 (+0.85)

Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 61.42 (+1.68), GERN: 2.73 (+0.04), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Medivation and Syngenta climb; Viacom, Marathon Oil fall
AP - Mon Aug 22, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
MDVN: 80.93 (+0.37), VIA: 44.42 (-0.77), MUR: 26.39 (-0.33), SYT: 87.68 (+0.43), PFE: 34.68 (-0.12), ODP: 3.62 (-0.06), MRO: 15.11 (+0.09), ISIL: 20.25 (+0.51), VIAB: 39.77 (-0.57), REGN: 393.40 (+0.85)

After Yesterday's Rally of 4.34% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $405.10 to a high of $422.30. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $415.82 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 393.40 (+0.85)

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
PR Newswire - Mon Aug 22, 7:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS). Regeneron has previously published details on how its proprietary VelociGene® and VelocImmune® technologies enabled the rapid identification and preclinical validation of these antibody candidates.
REGN: 393.40 (+0.85)

J&J (JNJ) Remicade Patent Invalid, Pfizer to Launch Inflectra?
Arpita Dutt - Zacks Investment Research - Thu Aug 18, 6:39AM CDT
With the court finding J&J's (JNJ) Remicade patent invalid, will Pfizer go for an "at-risk" launch?
JNJ: 119.08 (-0.26), PFE: 34.68 (-0.12), REGN: 393.40 (+0.85)

The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 306.03 (+0.40), BMRN: 95.19 (+1.30), AMGN: 170.13 (+0.07), ABBV: 64.03 (-0.07), REGN: 393.40 (+0.85)

Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.93 (+0.37), BIIB: 306.03 (+0.40), BMRN: 95.19 (+1.30), AMGN: 170.13 (+0.07), ABBV: 64.03 (-0.07), MNTA: 12.15 (+0.13), REGN: 393.40 (+0.85)

Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:31AM CDT
Adverum (ADVM) reported a narrower-than-expected loss in the second quarter. The company also decided to discontinue the development of lead candidate.
ADVM: 3.55 (-0.03), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74), REGN: 393.40 (+0.85)

What's in Store for Adverum (ADVM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:47AM CDT
Adverum Biotechnologies, Inc. (ADVM) is expected to report second-quarter 2016 results on Aug 11.
ADVM: 3.55 (-0.03), ADHD: 4.74 (-0.18), AVXS: 34.53 (-0.81), REGN: 393.40 (+0.85)

Uptrend Call Working As Regeneron Pharmaceuticals Stock Rises 15.7% (REGN)
Comtex SmarTrend(R) - Thu Aug 04, 1:51PM CDT
SmarTrend identified an Uptrend for Regeneron Pharmaceuticals (NASDAQ:REGN) on July 6th, 2016 at $364.02. In approximately 4 weeks, Regeneron Pharmaceuticals has returned 15.71% as of today's recent price of $421.23.
REGN: 393.40 (+0.85)

Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:33AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected second-quarter 2016 earnings of $2.10 per share.
ANIP: 61.42 (+1.68), SNY: 38.41 (-0.06), REGN: 393.40 (+0.85)

Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:22AM CDT
Regeneron???s (REGN) second-quarter 2016 earnings surpassed expectations.
REGN: 393.40 (+0.85)

Regeneron Reports Second Quarter 2016 Financial and Operating Results
PR Newswire - Thu Aug 04, 5:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2016 and provided a business update.
REGN: 393.40 (+0.85)

5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 32.10 (-0.03), BMRN: 95.19 (+1.30), ALNY: 69.02 (-0.83), TEVA: 50.90 (+0.51), REGN: 393.40 (+0.85)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...